Bio-Techne Corp (TECH) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. At $55.28, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk); Weak overall score: 4.7/10.
Bio-Techne develops and manufactures life science reagents, instruments, and services across Protein Sciences (~72% of FY2025 net sales) and Diagnostics & Spatial Biology (~28%) segments. Customers include pharmaceutical/biotech companies and academic researchers globally. No... Read more
Sell if holding. At $55.28, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk); Weak overall score: 4.7/10. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 4.7/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-11Item 5.02MEDIUMDr. Matt McManus (President, Diagnostics & Spatial Biology) transitioning out effective March 1, 2026. Steve Crouse (SVP, Analytical Solutions Division) appointed as successor DSS President. No reason cited for McManus departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Revenue shrinking — -0.4% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $55.28, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Earnings in 5 days (event risk); Weak overall score: 4.7/10. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $51.40. Score 4.7/10, moderate confidence.
Take-profit target: $62.88 (+13.8% upside). Prior stop was $51.40. Stop-loss: $51.40.
Earnings in 5 days (event risk); Weak overall score: 4.7/10; Weak growth.
Bio-Techne Corp trades at a P/E of 104.4 (forward 25.6). TrendMatrix value score: 4.7/10. Verdict: Sell.
23 analysts cover TECH with a consensus score of 4.0/5. Average price target: $72.
What does Bio-Techne Corp do?Bio-Techne develops and manufactures life science reagents, instruments, and services across Protein Sciences (~72% of...
Bio-Techne develops and manufactures life science reagents, instruments, and services across Protein Sciences (~72% of FY2025 net sales) and Diagnostics & Spatial Biology (~28%) segments. Customers include pharmaceutical/biotech companies and academic researchers globally. No single customer accounts for more than 10% of segment revenues, and no single supplier is material.